These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33013851)

  • 1. Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders.
    Bhatt ST; Bednarski JJ
    Front Immunol; 2020; 11():1988. PubMed ID: 33013851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
    Zaidman I; Rowe JM; Khalil A; Ben-Arush M; Elhasid R
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1043-1048. PubMed ID: 27016193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering.
    Klein OR; Bonfim C; Abraham A; Ruggeri A; Purtill D; Cohen S; Wynn R; Russell A; Sharma A; Ciccocioppo R; Prockop S; Boelens JJ; Bertaina A
    Cytotherapy; 2023 May; 25(5):463-471. PubMed ID: 36710227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
    Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
    Yu ZP; Ding JH; Sun AN; Chen BA; Ge Z; Wu DP
    Stem Cells Dev; 2019 Oct; 28(20):1376-1383. PubMed ID: 31464164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immunodeficiencies and Inherited Disorders in Children.
    Neven B; Diana JS; Castelle M; Magnani A; Rosain J; Touzot F; Moreira B; Fremond ML; Briand C; Bendavid M; Levy R; Morelle G; Vincent M; Magrin E; Bourget P; Chatenoud L; Picard C; Fischer A; Moshous D; Blanche S
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1363-1373. PubMed ID: 30876929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B Cell Reconstitution and Influencing Factors After Hematopoietic Stem Cell Transplantation in Children.
    van der Maas NG; Berghuis D; van der Burg M; Lankester AC
    Front Immunol; 2019; 10():782. PubMed ID: 31031769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Stem Cell Transplantation (HCT) for Severe Combined Immunodeficiency Patients: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
    Heimall J; Puck J; Buckley R; Fleisher TA; Gennery AR; Neven B; Slatter M; Haddad E; Notarangelo LD; Baker KS; Dietz AC; Duncan C; Pulsipher MA; Cowan MJ
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):379-387. PubMed ID: 28068510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.
    Shenoy S; Gaziev J; Angelucci E; King A; Bhatia M; Smith A; Bresters D; Haight AE; Duncan CN; de la Fuente J; Dietz AC; Baker KS; Pulsipher MA; Walters MC
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1313-1321. PubMed ID: 29653206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.
    Metheny L; de Lima M
    Expert Rev Hematol; 2019 Jan; 12(1):47-60. PubMed ID: 30582393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic cell transplantation for nonmalignant disorders.
    Tolar J; Mehta PA; Walters MC
    Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S166-71. PubMed ID: 22226101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children.
    Jacobsohn DA; Duerst R; Tse W; Kletzel M
    Lancet; 2004 Jul 10-16; 364(9429):156-62. PubMed ID: 15246728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children: A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution.
    Abdel-Azim H; Elshoury A; Mahadeo KM; Parkman R; Kapoor N
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1437-1446. PubMed ID: 28495643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.
    Mallhi K; Orchard PJ; Miller WP; Cao Q; Tolar J; Lund TC
    Bone Marrow Transplant; 2017 May; 52(5):726-732. PubMed ID: 28092353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.
    Minculescu L; Marquart HV; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Haastrup E; Fischer-Nielsen A; Reekie J; Sengelov H
    Front Immunol; 2019; 10():1997. PubMed ID: 31507601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.
    Hayashi RJ
    Front Immunol; 2020; 11():567423. PubMed ID: 33193340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency.
    Lum SH; Elfeky R; Achini FR; Margarit-Soler A; Cinicola B; Perez-Heras I; Nademi Z; Flood T; Cheetham T; Worth A; Qasim W; Amin R; Rao K; Chiesa R; Bredius RGM; Amrolia P; Abinun M; Hambleton S; Veys P; Gennery AR; Lankester A; Slatter M
    J Clin Immunol; 2021 Jan; 41(1):171-184. PubMed ID: 33141919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.
    Yi ES; Choi YB; Lee NH; Lee JW; Sung KW; Koo HH; Kang ES; Kim YJ; Yoo KH
    J Clin Immunol; 2018 Oct; 38(7):757-766. PubMed ID: 30151618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.